DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Serentil (Mesoridazine Besylate) - Summary

 
 



WARNING

SERENTIL® (MESORIDAZINE BESYLATE) HAS BEEN SHOWN TO PROLONG THE QTc INTERVAL IN A DOSE RELATED MANNER, AND DRUGS WITH THIS POTENTIAL, INCLUDING SERENTIL, HAVE BEEN ASSOCIATED WITH TORSADE DE POINTES-TYPE ARRHYTHMIAS AND SUDDEN DEATH. DUE TO ITS POTENTIAL FOR SIGNIFICANT, POSSIBLY LIFE-THREATENING, PROARRHYTHMIC EFFECTS, SERENTIL SHOULD BE RESERVED FOR USE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHO FAIL TO SHOW AN ACCEPTABLE RESPONSE TO ADEQUATE COURSES OF TREATMENT WITH OTHER ANTIPSYCHOTIC DRUGS, EITHER BECAUSE OF INSUFFICIENT EFFECTIVENESS OR THE INABILITY TO ACHIEVE AN EFFECTIVE DOSE DUE TO INTOLERABLE ADVERSE EFFECTS FROM THOSE DRUGS. (SEE WARNINGS, CONTRAINDICATIONS, AND INDICATIONS.)

 

SERENTIL SUMMARY

Serentil®

SERENTIL® (mesoridazine besylate), the besylate salt of a metabolite of thioridazine, is a phenothiazine antipsychotic. Serentil is 10-[2(1-methyl-2-piperidyl)ethyl]-2-(methyl-sulfinyl)-phenothiazine [as the besylate].

Serentil® (mesoridazine besylate) is indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. Due to the risk of significant, potentially life-threatening, proarrhythmic effects with Serentil treatment, Serentil should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. Consequently, before initiating treatment with Serentil, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product at an adequate dose, and for an adequate duration (see WARNINGS and CONTRAINDICATIONS).

      However, the prescriber should be aware that Serentil has not been systematically evaluated in controlled trials in treatment of refractory schizophrenic patients and its efficacy in such patients is unknown.


See all Serentil indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Serentil (Mesoridazine)

Schizophrenia Linked to Increased Breast Cancer Risk
Source: Medscape Psychiatry & Mental Health Headlines [2017.02.16]
Women with schizophrenia have a nearly twofold increased risk for breast cancer compared to women without schizophrenia, a finding that underscores the need for improved screening in this population.
Medscape Medical News

Medical News Today: B vitamins may improve schizophrenia symptoms
Source: Featured Health News from Medical News Today [2017.02.16]
The first meta-analysis of its kind reviews data from 18 clinical trials to conclude that B vitamins have a positive effect on schizophrenia symptoms.

B vitamins may improve schizophrenia symptoms
Source: Nutrition / Diet News From Medical News Today [2017.02.16]
The first meta-analysis of its kind reviews data from 18 clinical trials to conclude that B vitamins have a positive effect on schizophrenia symptoms.

Scientists find chemical pathway responsible for schizophrenia symptoms
Source: Psychology / Psychiatry News From Medical News Today [2017.02.09]
A new mouse study shows that adjusting the levels of kynurenic acid in the brain may significantly impact the symptoms of schizophrenia.

'Mirror game' test could secure early detection of schizophrenia, study shows
Source: Medical Devices / Diagnostics News From Medical News Today [2017.02.03]
Virtual reality could hold the key to unlocking an affordable, reliable and effective device to provide early diagnosis and management of schizophrenia.

more news >>

Published Studies Related to Serentil (Mesoridazine)

Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. [2007.11]
We compared the effects of single doses of thioridazine and mesoridazine on the heart rate-corrected QT (QTc) interval in healthy adult volunteers. QTc intervals and plasma concentrations of thioridazine, mesoridazine, and metabolites were measured after single oral doses of thioridazine hydrochloride 50 mg, mesoridazine besylate 50 mg, or placebo in a double-blind, crossover study...

more studies >>

Clinical Trials Related to Serentil (Mesoridazine)

Reducing Antipsychotic-Induced Weight Gain in Children With Metformin [Recruiting]
Recent but limited short term studies have shown that Metformin can slow down weight gain in obese children and in children with psychotropic-induced weight gain, two distinct pediatric populations that are at risk for obesity related co-morbid conditions. The purpose of this study is to conduct a long term prospective pilot cohort study to investigate the use of Metformin to prevent or decrease weight gain in two cohorts of children: 1) children with psychotropic induced weight gain on Metformin and 2) children with BMI above the 95th percentile on Metformin. Both study populations will be enrolled in a lifestyle weight management program

more trials >>


Page last updated: 2017-02-16

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015